FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Tetra Bio-Pharma Inc. Stock AnalysisComprehensive stock analysis for Tetra Bio-Pharma Inc. (TBPMF) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisTBPMF
TBPMF
Tetra Bio-Pharma Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
TBPMF
Home🔹Stocks🔹Tetra Bio-Pharma Inc.

Tetra Bio-Pharma Inc.

TBPMF•OTC

Tetra Bio-Pharma Inc.

TBPMF•OTC
Market cap
$7.87M
Sentiment

Your view on TBPMF

Mkt Cap
$7.87M
Sentiment
Your view
TBPMF
Tetra Bio-Pharma Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
TBPMF
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Tetra Bio-Pharma Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Guy Chamberland Master Herbal
Headquarters
2316 St. Joseph Boulevard, Orléans, ON, CA
Industry
Biotechnology
Sector
Healthcare
CEO
Guy Chamberland Master Herbal
Headquarters
2316 St. Joseph Boulevard, Orléans, ON, CA
Description

Tetra Bio-Pharma Inc., a biopharmaceutical company, engages in the discovery and development of cannabinoid-derived drugs for inflammation, pain, ophthalmology, and oncology. The company develops PLENITUDE to treat cancer-related pain in advanced cancer patients; REBORN for the treatment of breakthrough cancer pain; Reduvo for chemotherapy-induced nausea and vomiting; ARDS-003 for the treatment of sepsis and prevention of acute respiratory distress syndrome; and SERENITY to treat cancer cachexia. It also develops PPP003 for painful dry eye and uveitis pain; and HCC011 for hepatocellular carcinoma. Tetra Bio-Pharma Inc. has an agreement with Cellvera Global Holdings LLC for the co-development of ARDS-003 as a combination product with Qifenda 400MG (Favipiravir), a commercial-stage broad-spectrum antiviral drug. The company is headquartered in Orléans, Canada.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News